Allos Therapeutics, Inc.

Allos Therapeutics, Inc.

Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado. Allos Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company’s lead product candidate, pralatrexate (PDX) an antifolate, is in Phase II trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company’s other product candidate is RH1, a targeted chemotherapeutic agent, which is in a Phase I trial in patients with advanced solid tumors or non-Hodgkin's Lymphoma. In February 2009, the Company announced the final results from PROPEL, its pivotal Phase II trial of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This trial was conducted under an agreement reached with the United States Food and Drug Administration (FDA) under its special protocol assessment (SPA) process.

Contact Details

Office Address

Allos Therapeutics, Inc.
11080 CirclePoint Road, Suite 200
Westminster, CO, USA 80020
Phone: (303) 426-6262
Fax: (303) 412-9160


Chief Exec. Officer, Pres and Exec. Director

Mr. Paul L. Berns

Chief Financial Officer

Mr. David C. Clark

Business Reviews for Allos Therapeutics, Inc.

Related Companies